|Articles|July 20, 2016

What is an Infectious Disease That Needs Greater Attention Right Now?

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response at the Centers for Disease Control and Prevention (CDC) shares which infectious disease he feels needs greater attention.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC) shares which infectious disease he feels needs greater attention.

Interview Transcript (slightly modified for readability):

“I think that there are many threats out there, and it’s likely that the next threat won’t be something that we have specifically prepared for, like Zika (not really foreseeable.) Of all those things that we do know of out there in the world, a pandemic of influenza is something that we really do need to pay special attention to. That would be an animal influenza virus that develops the capability of being spread from person-to-person. We had an instance of that in 2009. That particular virus didn’t have the mortality rate or the severe illness rate that it might have so it was less severe than the previous three influenza pandemics. The next influenza pandemic, which we probably will have… we don’t know when, we don’t know how severe it will be—that’s something that we really need to work to be ready for.

In the long term, having a vaccine that is effective against more than the particular strains of influenza would be the answer. In the short term, we really need to be able to respond quickly to these instances of animal influenza viruses being identified in people. There is a laboratory requirement to have quick detection, and depending on the characteristics of that virus, developing diagnostic tests, evaluating the anti-influenza drugs. If it is spread from person-to-person, starting work on a vaccine. Getting all of those things in place and practiced so that in the case of an emergency, it’s as routine as it can be.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.